Live Breaking News & Updates on Neumora Therapeutics Daily

Stay updated with breaking news from Neumora therapeutics daily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Neumora Therapeutics (NASDAQ:NMRA) Receives New Coverage from Analysts at Bank of America

Bank of America initiated coverage on shares of Neumora Therapeutics (NASDAQ:NMRA – Free Report) in a research note released on Tuesday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $18.00 price target on the stock. NMRA has been the topic of a number of other research reports. Royal Bank of Canada assumed […] ....

United States , William Blair , Kristina Burow , Stifel Nicolaus , Royal Bank , Neumora Therapeutics Inc , Arch Venture Partners Xii Llc , Securities Exchange Commission , Neumora Therapeutics , Free Report , Marketbeat Ratings , Arch Venture Partners Xii , Exchange Commission , Director Kristina Burow , Get Free Report , Neumora Therapeutics Daily , Nasdaq Nmra , Initiated Coverage , Bank Of America Co ,

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of "N/A" by Brokerages

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) have received a consensus rating of “N/A” from the zero research firms that are covering the stock, MarketBeat Ratings reports. NMRA has been the subject of a number of research reports. Royal Bank of Canada assumed coverage on Neumora Therapeutics in a research note on […] ....

William Blair , Stifel Nicolaus , Neumora Therapeutics Inc , Arch Venture Partners Xii Llc , Royal Bank , Neumora Therapeutics Company Profile , Jpmorgan Chase Co , Amgen Inc , Neumora Therapeutics , Get Free Report , Marketbeat Ratings , Therapeutics Trading Down , Arch Venture Partners Xii , Get Free , Neumora Therapeutics Daily , Nasdaq Nmra ,

Neumora Therapeutics (NASDAQ:NMRA) Earns Overweight Rating from Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. started coverage on shares of Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. The firm set an “overweight” rating and a $21.00 price target on the stock. JPMorgan Chase & Co.‘s target price points to a potential upside […] ....

United States , Stifel Nicolaus , William Blair , Kristina Burow , Jpmorgan Chase Co , Neumora Therapeutics Inc , Amgen Inc , Securities Exchange Commission , Royal Bank , Neumora Therapeutics Company Profile , Neumora Therapeutics , Get Free Report , Marketbeat Ratings , Therapeutics Trading Down , Director Kristina Burow , Exchange Commission , Neumora Therapeutics Daily , Nasdaq Nmra , Initiated Coverage , Jpmorgan Chase Co ,

Neumora Therapeutics (NASDAQ:NMRA) Trading Down 8%

Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report)’s stock price was down 8% on Tuesday . The stock traded as low as $10.55 and last traded at $10.98. Approximately 189,086 shares were traded during trading, a decline of 62% from the average daily volume of 496,051 shares. The stock had previously closed at $11.94. Analyst […] ....

United States , Stifel Nicolaus , William Blair , Neumora Therapeutics Inc , Arch Venture Partners Xii Llc , Amgen Inc , Jpmorgan Chase Co , Neumora Therapeutics , Get Free Report , Therapeutics Trading Down , Arch Venture Partners Xii , Neumora Therapeutics Daily , Nasdaq Nmra ,

Insider Buying: Neumora Therapeutics, Inc. (NASDAQ:NMRA) Major Shareholder Acquires 24,504 Shares of Stock

Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) major shareholder Arch Venture Partners Xii, Llc purchased 24,504 shares of the business’s stock in a transaction on Wednesday, September 27th. The stock was acquired at an average price of $12.31 per share, for a total transaction of $301,644.24. Following the completion of the purchase, the insider […] ....

Arch Venture Partners Xii Llc , Securities Exchange Commission , Neumora Therapeutics Company Profile , Neumora Therapeutics Inc , Neumora Therapeutics , Get Free Report , Arch Venture Partners Xii , Exchange Commission , Venture Partners Xii , Neumora Therapeutics Daily , Nasdaq Nmra , Insider Trading , Nsider Trades ,